Future Tech

    What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma

    Moderna weighs rebranding mRNA vaccines as individual treatments to bypass public health polarization.

    Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”? That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccine...

    MTR

    MIT Technology Review

    Source

    MIT Technology ReviewRead the full story at MIT Technology Review
    What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma
    AI Analysis

    Generated insight by OnAirToday AI

    The shift in terminology from vaccine to therapeutic highlights how companies are rebranding mRNA technology to navigate politically charged skepticism. This linguistic pivot attempts to distance future life-saving treatments from the polarization surrounding COVID-19 immunization efforts.

    Powered by AI • Not a substitute for human analysisMore Insights →
    Read the full story at MIT Technology Review →
    Share

    Comments

    Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.

    0/1000